Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Surufatinib, and Temozolomide in Advanced Neuroendocrine Carcinoma
NCT07156019Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab in neuroendocrine carcinoma (NEC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07156019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156019.